

Table 2. Adverse events during subcutaneous infliximab treatment.

Adverse event	Patient cohort, n=274)	
	CD, n=104 (38.0)	UC, n=170 (62.0)
Mild adverse event		
- Abdominal pain	2 (0.7)	0
- Arthralgia	2 (0.7)	1 (0.4)
- Headache	1 (0.4)	1 (0.4)
- Local reactions	5 (1.8)	1 (0.4)
- Mild infection	2 (0.7)	0
- Rash	3 (1.1)	14 (5.1)
- Other*	2 (0.7)	2 (0.7)
Serious adverse event		
- Disease flare requiring hospitalisation	0	2 (0.7)
- Infection requiring hospitalisation	2 (0.7)	0

*Other adverse events included 1 self-reported memory-loss, 1 neutropenia, 1 self-reported faintness and 1 self-reported feeling of balance difficulties and dizziness.